RWE Cohort Package

ALK+ NSCLC 1L × Axitinib

Biomarker-defined cohort with comparator-ready real-world evidence (RWE) and real-world data (RWD). From clinical development to HTA submission, supported by a single dataset.

View Sample Snapshot Request Feasibility See Pricing

Estimated Cohort Size

n ≈ 2,200+

Cohort Definition

Biomarker-defined, 1L Specific

Commercial Intent

High

Starting At

Sample Snapshot (complimentary)

Proof Strategy

Publication-backed

Source: Multi-center EMR + Claims linkage | IRB-approved | De-identified | Quarterly refresh

SOC 2 Type IIHIPAAGDPR21 CFR Part 11IRB Approved

Why This Cohort Matters

The ALK+ NSCLC 1L cohort represents a critical commercial segment with growing demand for real-world evidence (RWE) and real-world data (RWD) benchmarks among competing pipeline assets.

With Axitinib established as a standard of care, there is significant demand for RWE data supporting comparative effectiveness, HTA submissions, and market access strategies.

Data Package Contents

Diagnosis + Biomarker Confirmation

Histological confirmation date, biomarker mutation type, testing method and timing

Treatment Initiation

Diagnosis-to-treatment interval, regimen selection rationale, ECOG PS and staging

Drug Exposure / Discontinuation / Switch

Axitinib duration and dosing, discontinuation reasons, second-line switch timing and regimen

Outcome Signals

Progression-free survival proxy, overall survival estimate, imaging-based progression date

Enrichment Layer

Comorbidity profile, metastasis status, composite biomarkers, healthcare expenditure data

Data Completeness by Block

Block 1

98%

Block 2

95%

Block 3

91%

Block 4

82%

Block 5

68%

Feasibility Assessment

Count-first

Is the cohort large enough?

We calculate patient counts by data source for the ALK+ NSCLC 1L cohort treated with Axitinib. Minimum statistical power threshold (n≥100) is verified immediately.

Comparator

Can a comparator arm be constructed?

We identify patients on alternative regimens within the same period and assess PSM/IPW matching feasibility for head-to-head comparison.

Enrichment

Is data linkage available?

We check availability of NGS panel results, imaging records, and claims data linkage for enrichment layers by source.

Deliverables

Sample Snapshot

A 2-3 page report summarizing cohort definition, demographics, and key variable distributions. Quick reference for internal decision-making.

Feasibility Memo

Technical document covering cohort size, comparator matching rate, and enrichment availability. Foundation for study design.

Pricing Range

Transparent pricing ranges based on data blocks and analysis scope. Ready for budget approval.

Evidence & Case Studies

Treatment pattern trends in ALK+ NSCLC 1L (2018–2024)

Case Study

Axitinib vs. comparators: real-world comparative effectiveness

White Paper

Biomarker subtype clustering analysis in ALK+ NSCLC 1L

Technical Brief

RWE-based healthcare expenditure benchmark dataset

Data Asset

Additional Context

Best-fit Teams

Clinical DevelopmentMedical AffairsHEORMarket AccessCommercial

Best-fit Assets

HTA comparative effectiveness analysis

Pipeline benchmarking

Market share analysis

Patient journey mapping

Pricing Logic

Block-based pricing structure. Select and purchase only the data you need.

Snapshot available free or at low cost to get started.

Start with a Sample Snapshot

From cohort verification to quote, completed in three steps.

1Snapshot2Feasibility3Quote

Get Sample Snapshot